Physician profile
Luke E Chesney
NPI 1225292162
$9,551.56
in general payments reported to CMS, 2019-2025
51 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $420 · 2021: $1,748 · 2022: $1,752 · 2023: $1,696 · 2024: $1,436 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,365.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,280.76 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $1,228.84 | 2019-2025 | |
| Lilly USA, LLC | $961.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $802.18 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $725.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.35 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $383.56 | 2021-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $357.72 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $357.46 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.10 | 2019-2024 | Xifaxan |
| Heartflow, INC. | $246.66 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $221.64 | 2019-2023 | Belsomra |
| Amarin Pharma, INC. | $185.64 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $117.81 | 2019-2022 | |
| Abiomed | $109.52 | 2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Chesney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.